| Dr Laura A Pallan, MD | |
|
960 Beaver Grade Rd, Coraopolis, PA 15108-2718 | |
| (412) 264-2020 | |
| (412) 375-7539 |
| Full Name | Dr Laura A Pallan |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 35 Years |
| Location | 960 Beaver Grade Rd, Coraopolis, Pennsylvania |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1932170230 | NPI | - | NPPES |
| 1541909 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | MD044348L (Pennsylvania) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lehigh Valley Eye Center, P.c. | 3072593508 | 57 |
News Archive
The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.
Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.
A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.
› Verified 8 days ago
| Entity Name | Associates In Ophthalmology Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639175045 PECOS PAC ID: 5496657561 Enrollment ID: O20040122000179 |
News Archive
The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.
Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.
A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.
› Verified 8 days ago
| Entity Name | Lehigh Valley Eye Center, P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356330369 PECOS PAC ID: 3072593508 Enrollment ID: O20040723000789 |
News Archive
The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.
Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.
A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.
› Verified 8 days ago
| Entity Name | Ophthalmology Consultants, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1265533889 PECOS PAC ID: 1658437702 Enrollment ID: O20090225000683 |
News Archive
The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.
Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.
A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laura A Pallan, MD 543 Backbone Rd, Sewickley, PA 15143-1486 Ph: (412) 264-2020 | Dr Laura A Pallan, MD 960 Beaver Grade Rd, Coraopolis, PA 15108-2718 Ph: (412) 264-2020 |
News Archive
The addition of Cetuximab (brand name Erbitux) to radiation therapy treatments does not increase the rate or duration of some side effects in the treatment of advanced head and neck cancers, according to a study presented at the plenary session today at the Multidisciplinary Head and Neck Cancer Symposium, co-sponsored by the American Society for Therapeutic Radiology and Oncology, the American Society for Clinical Oncology and the American Head and Neck Society.
The New York Stem Cell Foundation extends congratulations to Derrick Rossi, PhD, a member of the inaugural class of NYSCF-Robertson Investigators, who was named one of Time Magazine's 2010 "People Who Mattered" in the December 27, 2010 Person of the Year Issue.
Carnegie Mellon University researchers have identified a new anticonvulsant compound that has the potential to stop the development of epilepsy. The findings are published in the March issue of the journal Epilepsia.
A new discovery by UNC scientists describes how cells infected by the Epstein-Barr virus (EBV) produce small vesicles or sacs called exosomes, changing their cellular "cargo" of proteins and RNA. This altered exosome enters cells and can change the growth of recipient cells from benign to cancer-producing.
› Verified 8 days ago